Circio Holding ASA (”Circio” or ”the Company”) announced, on the 1st of June 2026, a research collaboration with GenAssist Ltd (”GenAssist”), a Suzhou-based biotechnology company developing tissue-specific AAV delivery technology. The parties will combine GenAssist’s tissue-targeted, liver-de-targeting capsids and promoters with Circio’s circVec expression cassette to develop next-generation AAV vectors. The collaboration pursues two distinct objectives: high muscle-specific expression at substantially reduced systemic doses for genetic muscle disease, and joint in vivo CAR-T candidates built on GenAssist’s T-cell-targeting capsids for oncology and autoimmune applications. No financial terms are disclosed.
Analyst Group’s View on the GenAssist Collaboration
The principal differentiator in this collaboration is the maturity of the delivery asset GenAssist contributes. Its lead capsid, LD-8S09, is reported to deliver approx. 10x higher functional muscle transduction than AAV9, the standard capsid used in most muscle- and cardiac-directed gene therapies. It is also reported to achieve near-complete liver de-targeting, with liver exposure at approx. 3% of AAV9 levels in non-human primates, the species generally regarded as most predictive of clinical translation. In practical terms, this implies more of the dose reaching muscle and far less accumulating in the liver, a principal site of AAV-related toxicity. These figures come from GenAssist’s own preclinical work and have not yet been independently verified, so they should be read as a promising signal rather than confirmed performance. Thus, given positive results via the collaboration, GenAssist’s capsids could tackle the dosing problem at the biodistribution level, directing more vector to muscle and less to the liver, while circVec contributes the high, durable protein expression that allows each transduced cell to do more. The two work at different stages, capsid selectivity governing where the vector goes and circVec governing how strongly and how long it is expressed once there. The central question the collaboration is designed to test, in vitro and in vivo, is whether combining the two delivers high muscle expression at the substantially lower doses neither technology achieves alone.
The choice of muscle as the lead indication is strategically meaningful. As a large-mass tissue, muscle requires very high AAV doses, the central driver of both the toxicity and cost that constrain the field. Combining tissue-targeted, liver-de-targeted capsids with circVec’s enhanced per-cell output addresses that dose-expression trade-off directly. This positions the program against high-value indications such as Duchenne muscular dystrophy, where GenAssist already holds a stated pipeline. It is also the first time Circio’s external network has engaged muscle, broadening the platform’s validated tissue footprint beyond heart, eye and CNS.
The in vivo CAR-T track introduces a delivery route Circio has not previously paired with circVec: capsid-based AAV delivery to T-cells. This differs from the LNP-based T-cell delivery evaluated with Acuitas, and from the myeloid-cell (CAR-M) route pursued with United Immunity, adding a third delivery format to Circio’s cell therapy work. Together with the muscle programme, it means a single agreement spans both of Circio’s development tracks, AAV gene therapy and in vivo cell therapy, though as with the broader cell therapy portfolio it remains a longer-dated optionality layer rather than a near-term value driver.
Finally, the agreement marks Circio’s first partnership in China. CTO Thomas B. Hansen has described China as a geography offering cutting-edge science and accelerated pathways to early clinical data. For a preclinical-stage platform, Analyst Group considers such pathways a potentially efficient route to the first in-human evidence capable of materially de-risking a circVec construct.
In summary, Analyst Group regards the GenAssist collaboration as a substantive addition to Circio’s 2026 partnership activity, combining a delivery asset with comparatively advanced preclinical data, entry into muscle as a new high-value indication, and exposure to both of Circio’s development tracks within a single agreement. That said, no financial terms have been disclosed, and both programmes are at an early preclinical stage where translational risk is the dominant variable. Weighing these factors, Analyst Group assesses that the collaboration adds another interesting partner to circVec’s delivery network and further supports the platform’s licensing appeal.
